Literature DB >> 16157695

(-)-7'-Isothiocyanato-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor.

Robert P Picone1, Atmaram D Khanolkar, Wei Xu, Lionel A Ayotte, Ganesh A Thakur, Dow P Hurst, Mary E Abood, Patricia H Reggio, Donna J Fournier, Alexandros Makriyannis.   

Abstract

The CB1 cannabinoid receptor has been shown to play important physiological roles in the central nervous system, as well as peripherally, and is a target for development of therapeutic medications. To gain insight on the ligand binding site(s) and structural features of activation, we designed and synthesized (-)-7'-isothiocyanato-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM841), a classical cannabinoid affinity label that incorporates an isothiocyanate substituent as an electrophilic reactive group capable of interacting irreversibly with a suitably located and properly oriented nucleophilic amino acid residue at or near the binding site. To obtain evidence for the site of covalent attachment of AM841, C6.47, identified in part by interactive ligand docking, was mutated to serine, alanine, and leucine to reduce or eliminate the nucleophilic character. Wild-type (WT) and mutant CB1 receptors were evaluated for their abilities to recognize a series of cannabinergic ligands. Each bound comparably to WT, excluding C6.47L, which displayed a reduced affinity for 3H-labeled (1R,3R,4R)-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-4-(3-hydroxypropyl)cyclohexan-1-ol (CP55940), AM841, 11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM4056), and (-)-7'-bromo-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM4043) and an improvement in affinity for (-)-trans-delta9-tetrahydrocannabinol (delta9-THC). The affinity of 3H-labeled [2,3-dihydro-5-methyl-3-[(4-morpholinyl)methyl]pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl](naphthyl)methanone (WIN55212-2) was unchanged across all mutants. It is noteworthy that AM841 was shown to bind irreversibly to WT CB1 but exhibited no covalent attachment with the mutants and behaved as an agonist suggesting irreversible attachment to C6.47 maintains CB1 in its active state. The evidence presented identifies C6.47 as the site of covalent bond formation with AM841 and combined with the binding data fully supports the molecular modeling. These studies present the first report of tandem applications of affinity labeling, site-directed mutagenesis, and interactive ligand docking for CB1.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16157695     DOI: 10.1124/mol.105.014407

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  48 in total

1.  Lipid bilayer molecular dynamics study of lipid-derived agonists of the putative cannabinoid receptor, GPR55.

Authors:  Evangelia Kotsikorou; Diane L Lynch; Mary E Abood; Patricia H Reggio
Journal:  Chem Phys Lipids       Date:  2010-12-24       Impact factor: 3.329

2.  hCB2 ligand-interaction landscape: cysteine residues critical to biarylpyrazole antagonist binding motif and receptor modulation.

Authors:  Richard W Mercier; Ying Pei; Lakshmipathi Pandarinathan; David R Janero; Jing Zhang; Alexandros Makriyannis
Journal:  Chem Biol       Date:  2010-10-29

3.  The membrane proximal region of the cannabinoid receptor CB1 N-terminus can allosterically modulate ligand affinity.

Authors:  Jonathan F Fay; David L Farrens
Journal:  Biochemistry       Date:  2013-11-08       Impact factor: 3.162

4.  Identification of essential cannabinoid-binding domains: structural insights into early dynamic events in receptor activation.

Authors:  Joong-Youn Shim; Alexander C Bertalovitz; Debra A Kendall
Journal:  J Biol Chem       Date:  2011-07-27       Impact factor: 5.157

Review 5.  Minireview: From the bench, toward the clinic: therapeutic opportunities for cannabinoid receptor modulation.

Authors:  Robert P Picone; Debra A Kendall
Journal:  Mol Endocrinol       Date:  2015-04-13

6.  Molecular-interaction and signaling profiles of AM3677, a novel covalent agonist selective for the cannabinoid 1 receptor.

Authors:  David R Janero; Suma Yaddanapudi; Nikolai Zvonok; Kumar V Subramanian; Vidyanand G Shukla; Edward Stahl; Lei Zhou; Dow Hurst; James Wager-Miller; Laura M Bohn; Patricia H Reggio; Ken Mackie; Alexandros Makriyannis
Journal:  ACS Chem Neurosci       Date:  2015-05-29       Impact factor: 4.418

7.  In vitro and non-invasive in vivo effects of the cannabinoid-1 receptor agonist AM841 on gastrointestinal motor function in the rat.

Authors:  R Abalo; C Chen; G Vera; J Fichna; G A Thakur; A E López-Pérez; A Makriyannis; M I Martín-Fontelles; M Storr
Journal:  Neurogastroenterol Motil       Date:  2015-09-20       Impact factor: 3.598

8.  3'-functionalized adamantyl cannabinoid receptor probes.

Authors:  Go Ogawa; Marcus A Tius; Han Zhou; Spyros P Nikas; Aneetha Halikhedkar; Srikrishnan Mallipeddi; Alexandros Makriyannis
Journal:  J Med Chem       Date:  2015-03-20       Impact factor: 7.446

Review 9.  Endogenous lipid activated G protein-coupled receptors: emerging structural features from crystallography and molecular dynamics simulations.

Authors:  Dow P Hurst; Marianne Schmeisser; Patricia H Reggio
Journal:  Chem Phys Lipids       Date:  2013-02-26       Impact factor: 3.329

10.  The expression level of CB1 and CB2 receptors determines their efficacy at inducing apoptosis in astrocytomas.

Authors:  Eiron Cudaback; William Marrs; Thomas Moeller; Nephi Stella
Journal:  PLoS One       Date:  2010-01-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.